KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to $178.6 million.

  • Halozyme Therapeutics' Cash from Operations rose 5479.56% to $178.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $611.0 million, marking a year-over-year increase of 5163.03%. This contributed to the annual value of $479.1 million for FY2024, which is 2328.87% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Cash from Operations of $178.6 million as of Q3 2025, which was up 5479.56% from $99.7 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Cash from Operations ranged from a high of $178.6 million in Q3 2025 and a low of $36.9 million during Q2 2021
  • Moreover, its 5-year median value for Cash from Operations was $87.0 million (2023), whereas its average is $96.8 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Cash from Operations soared by 190096.98% in 2021, and later crashed by 4279.98% in 2022.
  • Halozyme Therapeutics' Cash from Operations (Quarter) stood at $82.5 million in 2021, then dropped by 0.08% to $82.5 million in 2022, then increased by 24.14% to $102.4 million in 2023, then surged by 74.36% to $178.5 million in 2024, then increased by 0.07% to $178.6 million in 2025.
  • Its Cash from Operations was $178.6 million in Q3 2025, compared to $99.7 million in Q2 2025 and $154.2 million in Q1 2025.